<DOC>
	<DOCNO>NCT02604823</DOCNO>
	<brief_summary>This study efficacy safety peginterferon alfa-2a ( Pegasys ) naive , interferon- lamivudine-pretreated participant HBeAg-positive chronic HBV . Following 48 week treatment , 24 week period treatment-free follow-up . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Peginterferon Alfa-2a ( Pegasys ) Participants With Hepatitis B E-Antigen ( HBeAg ) -Positive Chronic Hepatitis B Virus ( HBV )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult participant 18 65 year age HBeAgpositive chronic HBV Treatmentnaive , receive respond relapse either conventional interferon lamivudine therapy . Antiviral interferonbased therapy chronic HBV within 6 month enrollment Coinfection active hepatitis A , C D virus human immunodeficiency virus ( HIV ) Evidence decompensated liver disease Medical condition associate chronic liver disease viral hepatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>